BioNTech Plans To Develop Malaria, Tuberculosis Vaccines In Africa

BioNTech SE (BNTX), in an update on plans to develop sustainable solutions to address infectious diseases on the African continent, said that it aims to develop the first mRNA-based vaccine for Malaria prevention with the initiation of a clinical trial by end of 2022.

BioNTech said it is evaluating sustainable mRNA vaccine production capacities in Africa; the Company's efforts are supported by the joint convening powers of the World Health Organization (WHO) and the Africa Centers for Disease Control and Prevention.

BioNTech's Malaria project is part of the 'eradicateMalaria' initiative, led by the kENUP Foundation, to accelerate the eradication of Malaria.

For Tuberculosis, BioNTech plans to begin clinical trials for testing a vaccine candidate in 2022.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Bobo's recalled one lot of Bobo's 4-pack Almond Butter Protein Bars for potentially containing undeclared peanuts, the U.S. Food and Drug Administration or FDA said in a statement. The recall was initiated after it was discovered that product containing peanuts was distributed in packaging that did not reveal the presence of peanuts on the ingredient deck. Birmingham, Michigan-based RFA Brands LLC, d/b/a myCharge is recalling about 67,000 units of myCharge powerbanks citing fire and burn risks, the U.S. Consumer Product Safety Commission said. The recall was initiated after myCharge received 30 reports of the powerbanks overheating, resulting in seven injuries as well as property damage to household flooring, walls and furniture. Comcast Corp. (CMCSA, CMCSK) on Thursday reported that profit for the third quarter doubled from last year, driven by 19 percent revenue growth amid significant growth across each of its businesses. Both adjusted earnings per share and quarterly revenues topped analysts' expectations. The company also declared a quarterly dividend.
Follow RTT